Depleting T cells in newly diagnosed autoimmune (type 1) diabetes - Are we getting anywhere?

Diabetes

Volumn 62, Issue 11, 2013, Pages 3669-3670

  Lernmark, Åke ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; IMMUNOSUPPRESSIVE AGENT; INSULIN; C PEPTIDE; MONOCLONAL ANTIBODY; TEPLIZUMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NOTE; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; DIABETES MELLITUS, TYPE 1; METABOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; HUMANS;

EID: 84891715314     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1207     Document Type: Note

References (13)

1. Leslie RD, Kolb H, Schloot NC, et al. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008;24:511- 519
2. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 25 July 2013 [Epub ahead of print]
3. Shakespeare W, Romeo and Juliet, John Danter, 1597
4. Hagopian W, Ferry RJ Jr, Sherry N, et al.; for the Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013;62:3901-3908
5. Herold KC, Gitelman SE, Ehlers MR, et al.; the AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62:3766-3774
6. Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013;56: 391-400
7. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Proté gé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378:487-497
8. Jensen RA, Gilliam LK, Törn C, et al.; Diabetes Incidence Study in Sweden (DISS) group. Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects. J Diabetes Complications 2007;21:205-213
9. Jensen RA, Agardh E, Lernmark A, et al.; DISS Group. HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later. PLoS One 2011; 6:e17569
10. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010;33:826-832
11. Long SA, Rieck M, Sanda S, et al.; Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012;61:2340-2348
12. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol 2013;9:92-103
13. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920